- Home
- GLNG vs OLMA Comparison
GLNG vs OLMA Comparison
Compare GLNG & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLNG
- OLMA
- Stock Information
- Founded
- GLNG 1946
- OLMA 2006
- Country
- GLNG Bermuda
- OLMA United States
- Employees
- GLNG N/A
- OLMA N/A
- Industry
- GLNG Marine Transportation
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- GLNG Consumer Discretionary
- OLMA Health Care
- Exchange
- GLNG Nasdaq
- OLMA Nasdaq
- Market Cap
- GLNG 4.4B
- OLMA 299.7M
- IPO Year
- GLNG N/A
- OLMA 2020
- Fundamental
- Price
- GLNG $40.69
- OLMA $4.65
- Analyst Decision
- GLNG Strong Buy
- OLMA Strong Buy
- Analyst Count
- GLNG 3
- OLMA 4
- Target Price
- GLNG $51.83
- OLMA $24.50
- AVG Volume (30 Days)
- GLNG 1.6M
- OLMA 825.6K
- Earning Date
- GLNG 01-01-0001
- OLMA 08-05-2025
- Dividend Yield
- GLNG 2.45%
- OLMA N/A
- EPS Growth
- GLNG N/A
- OLMA N/A
- EPS
- GLNG 0.03
- OLMA N/A
- Revenue
- GLNG $257,915,000.00
- OLMA N/A
- Revenue This Year
- GLNG $63.76
- OLMA N/A
- Revenue Next Year
- GLNG N/A
- OLMA N/A
- P/E Ratio
- GLNG $1,123.40
- OLMA N/A
- Revenue Growth
- GLNG N/A
- OLMA N/A
- 52 Week Low
- GLNG $29.29
- OLMA $2.86
- 52 Week High
- GLNG $44.36
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- GLNG 46.24
- OLMA 52.46
- Support Level
- GLNG $40.20
- OLMA $4.38
- Resistance Level
- GLNG $42.29
- OLMA $5.01
- Average True Range (ATR)
- GLNG 1.17
- OLMA 0.30
- MACD
- GLNG -0.17
- OLMA 0.05
- Stochastic Oscillator
- GLNG 19.07
- OLMA 63.64
About GLNG Golar Lng Ltd
Golar LNG Ltd is a midstream LNG company that operates in the transportation, regasification, liquefaction, and trading of LNG. The segment in which the group operates includes Shipping, FLNG (Floating Liquefaction Natural Gas vessels), and Corporate and other. It generates maximum revenue from the FLNG segment.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.